In part, this could be attributed to differences in the immune compartment, with KPC PDAC containing high levels of macrophages and myeloid-derived suppressor cells compared to B16-F10, potentially resulting in a tumor microenvironment more sensitive to CD47 immune checkpoint blockade when combined with NDV but not when anti-CD47 is administered alone as it appears to almost negatively impact survival.68 The gene discussed is CD47; the disease is neoplasm.